Please select the option that best describes you:
Topics:
Hematologic Malignancies • Pediatric Hematology/Oncology • Medical Oncology • Lymphoma • Hematology
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Would you consider holding, deferring, or skipping treatment?
For hepatitis, how would determine if toxicity was immunotherapy vs chemotherapy related?
Answer from: Medical Oncologist at Academic Institution
BV-AVD-related transaminitis is relatively common; however, even with Nivo-AVD, transaminitis is frequently observed, albeit at a lower frequency. Most of these events are self-limited and grade 1-2. Depending on the stage and severity of the event, dose holds can be employed; however, adverse event...
Sign in or Register to read more
Answer from: at Academic Institution
Agree with Dr. @Awan.
I have swapped BV for Nivo in some settings. Depends on lab findings and the clinical picture though.